Literature DB >> 35213024

Considerations for Generating Humanized Mouse Models to Test Efficacy of Antisense Oligonucleotides.

Irene Vázquez-Domínguez1, Alejandro Garanto2,3.   

Abstract

Over the last decades, animal models have become increasingly important in therapeutic drug development and assessment. The use of these models, mainly mice and rats, allow evaluating drugs in the real-organism environment and context. However, several molecular therapeutic approaches are sequence-dependent, and therefore, the humanization of such models is required to assess the efficacy. The generation of genetically modified humanized mouse models is often an expensive and laborious process that may not always recapitulate the human molecular and/or physiological phenotype. In this chapter, we summarize basic aspects to consider before designing and generating humanized models, especially when they are aimed to test antisense-based therapies.
© 2022. The Author(s).

Entities:  

Keywords:  Antisense oligonucleotides; Humanized models; In vivo drug testing; Model systems; Mouse model generation; Splicing defects

Mesh:

Substances:

Year:  2022        PMID: 35213024     DOI: 10.1007/978-1-0716-2010-6_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  46 in total

1.  Comparison of splice sites in mammals and chicken.

Authors:  Josep F Abril; Robert Castelo; Roderic Guigó
Journal:  Genome Res       Date:  2004-12-08       Impact factor: 9.043

2.  FDA Approval and Regulation of Pharmaceuticals, 1983-2018.

Authors:  Jonathan J Darrow; Jerry Avorn; Aaron S Kesselheim
Journal:  JAMA       Date:  2020-01-14       Impact factor: 56.272

Review 3.  Humanized mouse models: Application to human diseases.

Authors:  Ryoji Ito; Takeshi Takahashi; Mamoru Ito
Journal:  J Cell Physiol       Date:  2017-07-04       Impact factor: 6.384

4.  Comparison of the transcriptional landscapes between human and mouse tissues.

Authors:  Shin Lin; Yiing Lin; Joseph R Nery; Mark A Urich; Alessandra Breschi; Carrie A Davis; Alexander Dobin; Christopher Zaleski; Michael A Beer; William C Chapman; Thomas R Gingeras; Joseph R Ecker; Michael P Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-20       Impact factor: 11.205

5.  A Single Amino Acid Difference between Mouse and Human 5-Lipoxygenase Activating Protein (FLAP) Explains the Speciation and Differential Pharmacology of Novel FLAP Inhibitors.

Authors:  Jonathan M Blevitt; Michael D Hack; Krystal Herman; Leon Chang; John M Keith; Tara Mirzadegan; Navin L Rao; Alec D Lebsack; Marcos E Milla
Journal:  J Biol Chem       Date:  2016-04-16       Impact factor: 5.157

Review 6.  Humanized Mouse Models of Clinical Disease.

Authors:  Nicole C Walsh; Laurie L Kenney; Sonal Jangalwe; Ken-Edwin Aryee; Dale L Greiner; Michael A Brehm; Leonard D Shultz
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

7.  Modeling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice.

Authors:  Jasmin Barman-Aksözen; Paulina C Wiek; Vijay B Bansode; Frank Koentgen; Judith Trüb; Pawel Pelczar; Paolo Cinelli; Xiaoye Schneider-Yin; Daniel Schümperli; Elisabeth I Minder
Journal:  Dis Model Mech       Date:  2017-01-12       Impact factor: 5.758

Review 8.  Delivery of oligonucleotide-based therapeutics: challenges and opportunities.

Authors:  Suzan M Hammond; Annemieke Aartsma-Rus; Sandra Alves; Sven E Borgos; Ronald A M Buijsen; Rob W J Collin; Giuseppina Covello; Michela A Denti; Lourdes R Desviat; Lucía Echevarría; Camilla Foged; Gisela Gaina; Alejandro Garanto; Aurelie T Goyenvalle; Magdalena Guzowska; Irina Holodnuka; David R Jones; Sabine Krause; Taavi Lehto; Marisol Montolio; Willeke Van Roon-Mom; Virginia Arechavala-Gomeza
Journal:  EMBO Mol Med       Date:  2021-04-06       Impact factor: 12.137

9.  Modeling gene expression using chromatin features in various cellular contexts.

Authors:  Xianjun Dong; Melissa C Greven; Anshul Kundaje; Sarah Djebali; James B Brown; Chao Cheng; Thomas R Gingeras; Mark Gerstein; Roderic Guigó; Ewan Birney; Zhiping Weng
Journal:  Genome Biol       Date:  2012-06-13       Impact factor: 13.583

10.  Unexpected CEP290 mRNA splicing in a humanized knock-in mouse model for Leber congenital amaurosis.

Authors:  Alejandro Garanto; Sylvia E C van Beersum; Theo A Peters; Ronald Roepman; Frans P M Cremers; Rob W J Collin
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more
  1 in total

Review 1.  Splicing Modulation as a Promising Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses Example.

Authors:  Juliana Inês Santos; Mariana Gonçalves; Liliana Matos; Luciana Moreira; Sofia Carvalho; Maria João Prata; Maria Francisca Coutinho; Sandra Alves
Journal:  Life (Basel)       Date:  2022-04-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.